Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG. Goodman SG, et al. Among authors: poulouin y. Eur Heart J Cardiovasc Pharmacother. 2024 Apr 24:pvae025. doi: 10.1093/ehjcvp/pvae025. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.
Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, Garon G, Harrington RA, Jukema JW, Manvelian G, Stipek W, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Among authors: poulouin y. J Am Heart Assoc. 2023 Sep 19;12(18):e029216. doi: 10.1161/JAHA.122.029216. Epub 2023 Sep 13. J Am Heart Assoc. 2023. PMID: 37702079 Free PMC article. Clinical Trial. No abstract available.
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
Suc G, Schwartz GG, Goodman SG, Jukema JW, Manvelian G, Poulouin Y, Pordy R, Scemama M, Szarek M, Steg PG; ODYSSEY OUTCOMES Investigators. Suc G, et al. Among authors: poulouin y. BMC Ophthalmol. 2023 Jun 16;23(1):279. doi: 10.1186/s12886-023-03012-1. BMC Ophthalmol. 2023. PMID: 37328736 Free PMC article.
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Ostadal P, et al. Among authors: poulouin y. Lancet Diabetes Endocrinol. 2022 May;10(5):330-340. doi: 10.1016/S2213-8587(22)00043-2. Epub 2022 Apr 1. Lancet Diabetes Endocrinol. 2022. PMID: 35378068 Clinical Trial.
Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial.
Lopes RD, Guimarães PO, Schwartz GG, Bhatt DL, Bittner VA, Budaj A, Dalby AJ, Diaz R, Goodman SG, Harrington RA, Jukema JW, Kiss RG, Loy M, Pordy R, Poulouin Y, Szarek M, White HD, Steg PG; ODYSSEY OUTCOMES Investigators. Lopes RD, et al. Among authors: poulouin y. Am J Med. 2022 Jul;135(7):915-918. doi: 10.1016/j.amjmed.2022.02.016. Epub 2022 Mar 14. Am J Med. 2022. PMID: 35296402 Free article. Clinical Trial.